 |
PDBsum entry 3reb
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Protein binding
|
PDB id
|
|
|
|
3reb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
106 a.a.
|
 |
|
|
|
|
|
|
|
59 a.a.
|
 |
|
|
|
|
|
|
|
114 a.a.
|
 |
|
|
|
|
|
|
|
60 a.a.
|
 |
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Molecular design, Functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor nef.
|
 |
|
Authors
|
 |
S.Breuer,
S.I.Schievink,
A.Schulte,
W.Blankenfeldt,
O.T.Fackler,
M.Geyer.
|
 |
|
Ref.
|
 |
PLoS One, 2011,
6,
e20033.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Increased spread of HIV-1 and rapid emergence of drug resistance warrants
development of novel antiviral strategies. Nef, a critical viral pathogenicity
factor that interacts with host cell factors but lacks enzymatic activity, is
not targeted by current antiviral measures. Here we inhibit Nef function by
simultaneously blocking several highly conserved protein interaction surfaces.
This strategy, referred to as "wrapping Nef", is based on
structure-function analyses that led to the identification of four target sites:
(i) SH3 domain interaction, (ii) interference with protein transport processes,
(iii) CD4 binding and (iv) targeting to lipid membranes. Screening combinations
of Nef-interacting domains, we developed a series of small Nef interacting
proteins (NIs) composed of an SH3 domain optimized for binding to Nef, fused to
a sequence motif of the CD4 cytoplasmic tail and combined with a prenylation
signal for membrane association. NIs bind to Nef in the low nM affinity range,
associate with Nef in human cells and specifically interfere with key biological
activities of Nef. Structure determination of the Nef-inhibitor complex reveals
the molecular basis for binding specificity. These results establish Nef-NI
interfaces as promising leads for the development of potent Nef inhibitors.
|
 |
|
|
|
|
 |